Integrated BioPharma, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.9M
- Price
- $0.189
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 600
About
Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment provides warehousing and fulfilment services; and distributes raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
Quick stats
Shares outstanding31.1M
Computed float18.3M
Float / shares58.8%
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001016504
Websitehttps://ir.ibiopharma.com
AI Summary
AI-generated1/2
standardbearishearnings
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026
Integrated BioPharma reported FY26 revenue of $43.9 million, down 19.3% from $54.4 million, swinging from $2.0 million in operating income to a $2.7 million operating loss.
The fiscal fourth quarter was worse: revenue fell 31% to $9.8 million, with gross profit collapsing to just $28 thousand and a net loss of $1.4 million ($0.04 per share).
Management highlighted that the two largest contract-manufacturing customers represented roughly 90% of FY26 revenue, up from 84%, underscoring severe customer concentration risk.
Red flags
- revenue down 31% in Q4 and 19.3% for the fiscal year
- gross profit fell to ~$28K in Q4, near breakeven
- extreme customer concentration: two customers are ~90% of revenue